Literature DB >> 36083382

De-escalation of breast cancer treatment for Her2-positive breast cancer.

Parinita Swarnkar1, Lara Mokbel2, Kefah Mokbel3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 36083382     DOI： 10.1007/s10549-022-06737-7

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN： 0167-6806            Impact factor:   4.624


× No keyword cloud information.
  2 in total

1.  Pathologic response of ductal carcinoma in situ to neoadjuvant systemic treatment in HER2-positive breast cancer.

Authors:  Emma J Groen; Marieke E M van der Noordaa; Frederieke H van Duijnhoven; Jelle Wesseling; Michael Schaapveld; Gabe S Sonke; Ritse M Mann; Mette S van Ramshorst; Esther H Lips; Marie-Jeanne T F D Vrancken Peeters
Journal:  Breast Cancer Res Treat       Date:  2021-05-04       Impact factor: 4.872

2.  Efficacy of adjuvant trastuzumab in women with HER2-positive T1a or bN0M0 breast cancer: a population-based cohort study.

Authors:  Sanji Ali; Jace Hendry; Duc Le; Prosanta K Mondal; Amer Sami; Haji Chalchal; Kamal Haider; Osama Ahmed; Ali El-Gayed; Philip Wright; Mehrnoosh Pauls; Kate Johnson; Shahid Ahmed
Journal:  Sci Rep       Date:  2022-01-20       Impact factor: 4.379
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.